NA-Selank – Kodiac biolabs

Our opinion on this compoundSingle-lab provenance

37/100

PK-optimized Selank derivative with rational chemistry but single-lab evidence base and narrow bench utility

Here’s the thing about NA-Selank: it’s a well-conceived pharmacokinetic improvement on an already-interesting compound that happens to live almost entirely inside a single Russian research ecosystem. Selank itself, the parent heptapeptide, is registered in Russia as an intranasal anxiolytic and has a legitimate anxiolysis-without-sedation profile backed by tuftsin-receptor biology, GABAergic modulation, and BDNF transcriptional upregulation. The N-acetyl modification at the threonine N-terminus blocks the primary aminopeptidase cleavage site and extends plasma half-life roughly fivefold. The Amidate variant adds C-terminal amidation to block carboxypeptidase attack at the proline tail. Both modifications are rational, well-precedented chemistry. The resulting molecules are better candidates for parenteral administration with meaningful CNS exposure duration than the parent intranasal compound.

We like the underlying logic. The tuftsin-receptor angle is genuinely underexplored in Western literature. Tuftsin is an endogenous tetrapeptide with immunomodulatory activity on monocytes and natural killer cells, and the Selank backbone preserves that biology. With extended plasma exposure from the N-acetyl modification, the immune-modulatory component may operate differently than it does during the brief intranasal pulse of the parent compound. That’s an actually interesting research question. The BDNF upregulation claims, meanwhile, slot into a crowded field where every third peptide is said to boost neurotrophins, so we weight that more cautiously.

The evidence situation is the central problem. Published characterization is dominated by the Institute of Molecular Genetics RAS group, principally in Russian-language journals, with very limited independent replication. That puts NA-Selank in similar epistemic territory to Epitalon or classic Khavinson peptides: real preclinical work exists, but the absence of external replication means the error bars are wide. There are no human trials on the NA variants specifically. The parent Selank’s Russian registration provides some translational signal, but extrapolating from approved-intranasal to research-parenteral is a meaningful step with its own unknowns about exposure kinetics and CNS distribution in humans.

What NA-Selank does well as a research tool is give investigators a parenteral-compatible version of the Selank backbone for studying CNS anxiolytic peptide pharmacology, tuftsin-receptor biology, and the differential immunomodulatory profile under sustained versus pulsed exposure. That’s a legitimate but narrow use case. If your program isnt already anchored in peptide anxiolytics or tuftsin biology, theres little reason to prioritize this over compounds with better-replicated preclinical packages. For investigators already in that space, the extended-PK variants are worth having in the toolkit, but theyre supplementary tools rather than foundational ones. A score of 37 reflects exactly that: interesting enough to catalog, not compelling enough to center a program on.

Novelty: 45
Mechanism promise: 42
In-category differentiation: 38
Evidence quality: 25
Translational signal: 28
Research bench value: 38

Rationale NA-Selank’s N-acetylation and amidation modifications are pharmacokinetically sound and produce a legitimate parenteral research tool, but the evidence base is dominated by a single Russian research consortium with minimal independent replication, and the compound’s utility is narrow outside tuftsin or peptide anxiolytic research programs.

N-acetylated Selank derivatives with extended pharmacokinetics

N-terminal-acetylated and amidated variants of the heptapeptide anxiolytic Selank, designed to extend plasma and central nervous system exposure beyond the parent peptide.

Abstract

NA-Selank (N-acetyl-Thr-Lys-Pro-Arg-Pro-Gly-Pro) and NA-Selank Amidate (the same N-acetylated heptapeptide with C-terminal amidation, Pro-NH2) are N-terminal-modified derivatives of Selank, the seven-residue peptide anxiolytic developed at the Russian Academy of Sciences as an analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg). The parent Selank is registered as a medicine in the Russian Federation as an intranasal anxiolytic at 0.15 percent solution; the principal pharmacological signature is anxiolysis without sedation, modest pro-cognitive activity, and immunomodulation through tuftsin-receptor binding on monocytes and natural killer cells. Selank itself has a short plasma half-life of minutes and is administered intranasally to leverage direct olfactory and trigeminal transport to the central nervous system; the N-acetyl modification at the threonine N-terminus blocks the principal aminopeptidase cleavage site and extends plasma half-life by approximately 5-fold, while the C-terminal amidation in the Amidate variant similarly blocks carboxypeptidase cleavage at the proline C-terminus. The combined modifications produce a heptapeptide with substantially extended exposure suitable for parenteral administration with central nervous system effect. Mechanism includes BDNF transcriptional upregulation, GABAergic and serotonergic modulation, and tuftsin-receptor immunomodulation. Both NA-Selank and NA-Selank Amidate are research-grade peptides without regulatory approval; published characterization is principally in Russian-language journals and is dominated by the originating Institute of Molecular Genetics RAS research group. Investigators should treat the extended-PK variants as research tools for studying parenteral Selank pharmacology and should consider that the immune-modulatory profile may be more pronounced with extended exposure than with the brief intranasal pulse achieved by the parent.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1333Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.